Roivant Sciences (ROIV) P/B ratio

P/B ratio today
5.9×

Roivant Sciences (ROIV) trades at 5.9× its book value per share at the end of fiscal 2026. At the end of fiscal 2026 (March 31, 2026) its P/B ratio was 4.2×. That is 171.9% higher than the 1.6× of fiscal 2025. Figures as of 18 Nov 2026, 04:42 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/B ratio today
5.9×
P/B ratio, fiscal 2026
4.2×
Change on fiscal 2025
+171.9%
Highest on record
4.5×fiscal 2023
Lowest on record
1.5×fiscal 2024
Fiscal years on record
52022–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Roivant Sciences P/B ratio, in more detail

Today's figure is 39.7% above the fiscal 2026 year-end.

Across the 5 fiscal year-ends on record (2022–2026), the highest was 4.5× in fiscal 2023 and the lowest 1.5× in fiscal 2024. Today's P/B ratio is above every one of the 5 fiscal year-ends on record; their median is 2.0×.

History · 5 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Roivant Sciences P/B ratio, year by year

Roivant Sciences (ROIV) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today5.9×—$38.71—
20264.2× 171.9% up$27.70$6.52
20251.6× 6.4% up$10.09$6.46
20241.5× 67.7% down$10.54$7.18
20234.5× 127.5% up$7.38$1.62
20222.0×—$4.94$2.47
2021——$9.78—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

P/B ratio at health care companies of similar size

P/B ratio of Roivant Sciences and comparable companies
CompanyP/B ratio
Labcorp Holdings LH3.5×
DexCom DXCM11.1×
Roivant Sciences ROIV6.2×
West Pharmaceutical Services WST9.1×
Quest Diagnostics DGX3.9×

Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.

More on ROIV

Roivant Sciences, figure by figure

Roivant Sciences (ROIV) overview: price, valuation and scorecardAll health care companies by market value

Roivant Sciences P/B ratio: questions and answers

What is Roivant Sciences's P/B ratio?

Roivant Sciences (ROIV) trades at 5.9× its book value per share at the end of fiscal 2026. At the end of fiscal 2026 (March 31, 2026) its P/B ratio was 4.2×. That is 171.9% higher than the 1.6× of fiscal 2025.

Is Roivant Sciences's P/B ratio high or low compared with its own history?

Today's P/B ratio is above every one of the 5 fiscal year-ends on record; their median is 2.0×.

What are the highest and lowest P/B ratio figures on record for Roivant Sciences?

Across the 5 fiscal year-ends on record (2022–2026), the highest was 4.5× in fiscal 2023 and the lowest 1.5× in fiscal 2024.

How is Roivant Sciences's P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Roivant Sciences (ROIV) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/ROIV/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.